Speciality Medicines Limited Sets Sights on Growth with IPO Launch
Speciality Medicines Limited plans to open its IPO on March 20, 2026, aiming to raise ₹29.14 Crore. The proceeds will be used for R&D, international product registration, and marketing efforts. This milestone is set to aid the company's growth in India's specialty pharmaceutical market and globally.
- Country:
- India
Mumbai, India – Speciality Medicines Limited, engaged in marketing and distributing specialty pharmaceuticals, will launch its Initial Public Offering (IPO) on March 20, 2026, to raise ₹29.14 Crore. The shares will list on the BSE SME platform with an issue size of 23,50,000 equity shares, priced between ₹117 and ₹124 each.
The capital raised from the IPO will fund a new Research and Development center, international product registration, and marketing activities. Chairman Parth Goyani emphasizes the company's goal to expand its product portfolio and global market presence, targeting critical therapeutic areas like oncology and neurology.
Brijesh Parekh from Unistone Capital, the Book Running Lead Manager, highlights the company's robust distribution network and expanding international presence. The IPO proceeds will increase Speciality Medicines Limited's capacity for sustainable growth in the pharmaceutical industry.
ALSO READ
-
Trenzet Infra Ltd Set for IPO as Railway Projects Gain Momentum
-
CMPDIL's IPO: A Deep Dive into Coal India's Ambitious Share Sale
-
Polite Powertech Ltd. Gears Up for IPO to Boost Infrastructure Growth
-
IFC Invests $15M in Sunway Healthcare IPO to Expand Hospital Network in Malaysia
-
SBI Mutual Fund's Ambitious IPO Plans: A Historic Move in Asset Management